Clinical Trials Logo

Acute Leukemia in Remission clinical trials

View clinical trials related to Acute Leukemia in Remission.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03885947 Completed - Clinical trials for Myelodysplastic Syndromes

VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

Start date: February 21, 2019
Phase: Phase 1
Study type: Interventional

In this Phase I study, the study team will evaluate the safety of Valproic Acid (VPA) expanded cord blood stem cells defined by the lack of serious infusion reactions or graft failure in patients with hematological malignancies undergoing umbilical cord blood transplantation. Moreover, the study team will also evaluate time to neutrophil and platelet engraftment as well as transplant related outcomes such as graft versus host disease (GVHD), treatment related mortality (TRM), and overall survival (OS).

NCT ID: NCT03574012 Completed - Lymphoma Clinical Trials

SmART Heart: Study of mHealth Apps to Reduce Cancer-Treatment Effects on the Heart

Start date: August 31, 2018
Phase: N/A
Study type: Interventional

This pilot trial studies how well education and mobile health applications work in reducing the effects of cancer treatment on the heart in participants with blood cancers that are in remission. Education and mobile health applications may be effective ways to manage heart health and to reduce future heart disease risk in participants with blood cancers.

NCT ID: NCT03018223 Completed - Multiple Myeloma Clinical Trials

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Start date: January 31, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs. host disease (GVHD) after receiving a hematopoietic cell transplant from a related partially matched (haploidentical) donor. As part of the treatment for their blood cancer, participants need a hematopoietic cell transplantation (HCT) to improve their chances of cure. In any HCT, after the stem cell infusion is given, a combination of drugs is needed to prevent GVHD and facilitate acceptance of the graft.